Related Experiment Video
Updated: Feb 17, 2026
10:32
Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
19.4K
Medication Adherence Decisions in Patients With Schizophrenia
Martijn J Kikkert1,2, Jack Dekker2
1Research Department, Arkin Mental Health Care Institute, Klaprozenweg 111, Amsterdam, Noord Holland 1033 NN, The Netherlands. martijn.kikkert@arkin.nl.
The Primary Care Companion for CNS Disorders
|December 8, 2017
Summary
Medication nonadherence in schizophrenia is common, impacting relapse risk. A new model explains patient decisions about medication, considering factors like side effects and social influences, to improve adherence.
Area of Science:
- Psychiatry
- Psychology
- Health Services Research
Background:
- Medication nonadherence is prevalent in schizophrenia, affecting around 50% of patients.
- This nonadherence is linked to increased relapse rates and hospitalizations.
- Underlying mechanisms driving nonadherence remain poorly understood.
Purpose of the Study:
- To present a model of medication adherence decisions in schizophrenia patients.
- The model integrates quantitative and qualitative findings with psychological decision theory.
- To provide a framework for clinicians and researchers developing adherence interventions.
Main Methods:
- Utilized quantitative and qualitative study results.
- Applied principles of psychological decision theory.
- Developed a patient-centered model focusing on medication's function and meaning.
Main Results:
- The model explains medication adherence decisions from the patient's perspective.
- It incorporates key factors: insight, side effects, efficacy, and social influences.
- The model helps explain persistent high rates of nonadherence.
Conclusions:
- The developed model offers insights into schizophrenia medication adherence.
- Understanding patient perspectives on medication is crucial for adherence.
- The model has implications for clinical practice and intervention development.
Related Concept Videos
01:28Drug Therapy
315
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
315
01:26Psychosis: Goals of Pharmacotherapy
551
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
551
01:28Psychosis and Antipsychotic Drugs: Overview
957
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
957
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
284
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
284
01:15Drug Dosing: Geriatric Patients
286
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
286
01:23Antidepressant Drugs: MAOIs and Other Agents
970
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
970